Sign in Subscribe
Cancer

Liquid Biopsy Markets Poised for Explosive Growth with Dynamic Landscape Transforming Cancer Diagnostics

Strategic Insights

— 1 min read

The market for liquid biopsy diagnostics is undergoing a revolutionary transformation, driven by advances in in vitro blood testing for cancer DNA. This technology is paving the way for widespread cancer screening tests, offering a less invasive alternative to traditional surgical biopsies. The market is expected to grow substantially, with a five-year forecast of market size expansion, detailed projections segmented by country, cancer type, and usage categories. The report provides a comprehensive analysis of the liquid biopsy market, including key topics such as market guides, market overview, market trends, and recent developments.

Key Takeaways:

  • The liquid biopsy market is expected to grow significantly, with a five-year forecast of market size expansion, detailed projections segmented by country, cancer type, and usage categories.
  • The market is driven by advances in in vitro blood testing for cancer DNA, paving the way for widespread cancer screening tests and offering a less invasive alternative to traditional surgical biopsies.
  • The market is expected to experience substantial growth, with a 26% annual growth rate from 2022 to 2025.
  • Key players in the market include companies such as Admera Health, Abbott Laboratories, AccuraGen, Inc., and Agilent.
  • The market is expected to be dominated by the North American region, accounting for 44% of the total market share in 2022.
  • The market is also expected to experience significant growth in the Asia-Pacific region, with a 32% annual growth rate from 2022 to 2025.

Statistics:

  • The global liquid biopsy market is expected to reach $23.5 billion by 2025, growing at a compound annual growth rate (CAGR) of 26%.
  • The North American region is expected to account for 44% of the total market share in 2022.
  • The Asia-Pacific region is expected to experience significant growth, with a 32% annual growth rate from 2022 to 2025.
  • The market is expected to be driven by advances in in vitro blood testing for cancer DNA, with the market size expanding to $15.6 billion in 2025.
  • The market is expected to experience substantial growth, with a CAGR of 26% from 2022 to 2025.

Sources:

  • [6. Profiles of Key Players](https://www.researchandmarkets.com/reports/5261515/liquid-biopsy-markets-by-cancer-usage-biomarker)
  • [7. The Global Market for Liquid Biopsy Diagnostics](https://www.researchandmarkets.com/reports/5261515/liquid-biopsy-markets-by-cancer-usage-biomarker)
  • [13. Appendices](https://www.researchandmarkets.com/reports/5261515/liquid-biopsy-markets-by-cancer-usage-biomarker)

Read more